High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion

Leukemia

Volumn 16, Issue 9, 2002, Pages 1725-1734

  Keeshan, K ^a   Cotter, T G ^a   McKenna, S L ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bcl 2 family; Bcr Abl; Drug resistance; Mitochondria

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BCR ABL PROTEIN; CASPASE; CYTOTOXIC AGENT; ETOPOSIDE; INTERLEUKIN 3; LY 249002; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; STAT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL LINE; CHRONIC MYELOID LEUKEMIA; CYTOSOL; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME INACTIVATION; INTRACELLULAR TRANSPORT; LEUKEMOGENESIS; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN TRANSPORT;

EID: 0036739778     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402576     Document Type: Article

References (49)

1. Elevated Bcr-Abl levels are sufficient for a haematopoietic cell line to acquire a drug resistant phenotype
2. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-xL
3. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
4. The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X
5. Molecular abnormalities in chronic myeloid leukemia: Deregulation of cell growth and apoptosis
6. P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2
7. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation
8. The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells
9. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells
10. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis
11. Bcr/Abl activates transcription of the Bcl-X gene through STAT5
12. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
13. Activation of the phosphatidylinositol 3-kinase/Akt pathway protects against interleukin-3 starvation but not DNA damage-induced apoptosis
14. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line
15. The Bcl-2 protein family
16. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects
17. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant
18. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf
19. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt
20. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis
21. bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria
22. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis
23. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis
24. Movement of Bax from the cytosol to mitochondria during apoptosis
25. The substitution of the C-terminus of bax by that of bcl-xL does not affect its subcellular localization but abrogates its pro-apoptotic properties
26. The putative pore-forming domain of Bax regulates mitochondrial localization and interaction with Bcl-X(L)
27. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity
28. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
29. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)
30. Conversion of Bcl-2 to a Bax-like death effector by caspases
31. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability
32. Proapoptotic BH3-only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity
33. Bh3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability
34. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
35. Breaking the mitochondrial barrier
36. An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells
37. Apoptosis in chronic myelogenous leukemia: Studies of stage-specific differences
38. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines
39. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
40. Role of phosphatidylinositol 3-kinase and specific protein kinase B isoforms in the suppression of apoptosis mediated by the Abelson protein-tyrosine kinase
41. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and ST1571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571
42. Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death
43. Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling
44. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
45. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death
46. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death
47. Conformation of the Bax C-terminus regulates subcellular location and cell death
48. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells
49. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155